Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA “Unable” To Act On Hylenex By User Fee Deadline

This article was originally published in The Pink Sheet Daily

Executive Summary

Approval of Halozyme Therapeutics’ hyaluronidase product could be bogged down by ongoing legal arguments over Ista’s Vitrase exclusivity.
Advertisement

Related Content

Halozyme Expects Hylenex Exclusivity Issues To Be Resolved Soon
Halozyme Expects Hylenex Exclusivity Issues To Be Resolved Soon
Vitrase Journal Ad Lacks Risk Information, FDA Says
Vitrase Journal Ad Lacks Risk Information, FDA Says
Sandoz Sues FDA For Inaction On Omnitrope NDA
Baxter/Halozyme Hyaluronidase Enhanze SC Could See Approval By September
Baxter/Halozyme Hyaluronidase Enhanze SC Could See Approval By September
Vitrase Gains New Molecular Entity Status Due To Lack Of Characterization
Amphastar's Spreading Agent Amphadase Clears FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS062950

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel